Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
Ratings
Vertex Pharmaceuticals: Strong Market Position and Promising Growth Potential Justify Buy Rating
12d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Promising Advancements in Kidney Disease Treatments Drive Buy Rating
13d ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals presents new data on CASGEVY at ASH
13d ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals price target raised to $564 from $516 at Morgan Stanley
15d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals Positioned for Blockbuster Success in Rare Disease Market with Strong Renal Franchise and Promising Clinical Data
15d ago
VRTX
Premium
The Fly
Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
17d ago
M
W
Premium
The Fly
Oracle initiated, Uber upgraded: Wall Street’s top analyst calls
17d ago
W
WEN
Premium
The Fly
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
18d ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating
18d ago
VRTX
Premium
The Fly
Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls
1M ago
AZO
BMY
Premium
The Fly
Scotiabank starts 10 large cap drugmakers with ‘out-of-consensus’ positive view
1M ago
BMY
JNJ
Premium
The Fly
Vertex Pharmaceuticals initiated with an Outperform at Scotiabank
1M ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Hold Rating Amid High Valuation and Uncertain Growth Prospects Beyond Cystic Fibrosis
1M ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development
1M ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating
1M ago
VRTX
Premium
Ratings
Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data
1M ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Promising Data Amidst Competitive Renal Landscape and Investment Complexities
1M ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals announces updated data from RUBY-3 study of povetacicept
1M ago
VRTX
Premium
The Fly
Vertex Pharmaceuticals price target lowered to $546 from $553 at UBS
1M ago
VRTX
Premium
Ratings
Vertex Pharmaceuticals: Strong Revenue Performance and Promising Prospects Justify Buy Rating
1M ago
VRTX
Premium
The Fly
FDA awards second batch of National Priority Vouchers
1M ago
GSK
JNJ
Premium
Company Announcements
Vertex Pharmaceuticals Q3 2025 Earnings Call Highlights
2M ago
VRTX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
